Navigation Links
U.S. Sleep Therapy Market Driven by Growing Population Diagnosed with Sleep Apnea: Led By Philips Respironics, ResMed and Fisher & Paykel
Date:9/3/2014

Vancouver, BC (PRWEB) September 03, 2014

According to a report by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the U.S. anesthesia, respiratory and sleep-management device market will reach approximately $4 billion by 2019, with strong growth being driven by the sleep therapy devices market. This market accounts for just over a third of the overall market and includes positive airway pressure (PAP) therapeutic machines and sleep therapy interfaces.

The sleep therapy market will be driven by the growing awareness among the general population of both the symptoms of sleep apnea and the potential dangers associated with leaving the condition untreated. There are three types of sleep apnea cases: obstructive sleep apnea (OSA), central sleep apnea (CSA) and complex sleep apnea, which happens when the apneic events are caused by a combination of OSA and CSA factors. The most common form of sleep apnea is OSA, which accounts for approximately 80% of all sleep apnea cases.

There are numerous treatments available for sufferers of obstructive sleep apnea. The simplest of these treatments involve changes in lifestyle, including weight loss, avoiding respiratory depressants such as alcohol and/or smoking. “It is estimated that 70% to 85% of patients that are diagnosed with sleep apnea are recommended some form of (PAP) treatment,” says Dr. Kamran Zamanian, CEO of iData. PAP machines are flow generators that force air into the laryngeal cavity via a mask that a patient wears as they sleep.

Competitors leading this market include Philips Respironics, Fisher & Paykel and ResMed with their easy breathe waveform, which intelligently recreates a patient’s breathing patterns. Within the sleep therapy industry, low patient compliance to traditional techniques has been the most significant driver of new research and development. Companies have been quick to introduce new features, such as new designs, gel or silicone cushions or customized fittings meant to address individual patient needs and increase the comfort of the patient while using a PAP device.

For More Information
The report for U.S. anesthesia, respiratory and sleep-management device market include anesthesia delivery units (ADUs), anesthesia patient monitors, anesthesia information management systems (AIMS), anesthesia disposables, ventilators, nebulizers, respiratory disposables, oxygen therapy devices, therapeutic obstructive sleep apnea devices and sleep diagnostic devices.

Request a complimentary synopsis from the report

About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12130320.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference
2. Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis
3. Less Sleep in Teen Years Tied to More Pounds at 21
4. Sleep Apnea Treatment Helps Seniors, Study Finds
5. Sleep Drunkenness Is Common and Linked to Other Behavior Issues
6. Dental Sleep Apnea Appliances Have Advantages Over Traditional Solutions, Woodland Hills Dental Expert Says
7. Getting Back to School Sleep Schedules
8. Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States
9. Learning to play the piano? Sleep on it!
10. Seniors Sleep Woes May Be Linked to Loss of Brain Cells
11. Teen sleeplessness piles on risk for obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: